IGF1R and head and neck squamous cell carcinoma: Shin and colleagues in 2013 tested the effectiveness of the anti-IGF1R antibody cixutumumab (cix) on a panel of human head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) cell lines (38).